Oura IPO Launch
Smart-ring maker Oura targets a $15.6 billion valuation in its U.S. IPO.
Anonymous
Key Points
1
Eli Lilly has indicated it may purchase up to $100 million of Oura shares, while investment firm Dragoneer has expressed interest in buying as much as $300 million.
2
Oura’s lead underwriters are Goldman Sachs, Morgan Stanley and J.P. Morgan, with Allen & Company and Jefferies serving as joint lead book-running managers.
3
Oura’s Ring 5 is priced at $399, or $499 for premium finishes, while its membership costs $5.99 per month or $69.99 annually; membership revenue grew 121% year over year to $240.5 million for the nine months ended June 30.
4
The company projects that its paid membership base will reach approximately 5.7 million by the end of fiscal 2026, up nearly twofold from the prior year.
5
Oura is facing a proposed class-action lawsuit filed in August alleging that its ring cannot accurately measure sleep stages, adding a legal risk as the company moves toward public trading.
Finnish smart-ring maker Oura launched its U.S. IPO with 50 million shares priced at $40 to $44 each, potentially valuing the company at $15.6 billion and raising up to $2.2 billion in gross proceeds MedTech Dive. The company will receive about $594 million from its 13.5 million primary shares, while existing shareholders sell 36.5 million shares. Eastern Herald
Oura reported $1.21 billion in revenue for nine months ended June 30, up 74% year over year, with $60.8 million in net income MedTech Dive. The company sold 3.6 million rings last year and has more than 5 million paid members. Trading on Nasdaq under ticker OURA is expected to begin next week Law360.
Eli Lilly and Dragoneer Back the Public Offering
Pharmaceutical giant Eli Lilly announced plans to buy up to $100 million of Oura shares in the IPO Eastern Herald. Investment firm Dragoneer has also expressed interest in purchasing as much as $300 million worth of shares. These cornerstone investments signal confidence from major healthcare players in Oura's wearable technology.
Membership Revenue Drives the Valuation
Oura's subscription business is the real profit engine. Nine-month membership revenue hit $240.5 million, up 121% year over year, with an 89% gross margin MedTech Dive. The company charges $5.99 per month or $69.99 annually for memberships. The Ring 5 hardware costs $399, or $499 for premium finishes.
Analysts say investors are pricing Oura like a software company because of its high-margin recurring revenue model. The company projects its paid membership base will reach 5.7 million by the end of 2026, nearly double the prior year. About 72% of Oura's members identify as female, reflecting strong appeal in women's health tracking.
Sleep Tracking Lawsuit Adds Legal Risk
Oura faces a proposed class-action lawsuit filed in August alleging the ring cannot accurately measure sleep stages Law360. The plaintiff claims Oura's "95% accuracy" claim is misleading because it only measures simple sleep-versus-wake detection. Real four-stage sleep tracking accuracy sits closer to 53% to 76%, the lawsuit alleges.
Oura maintains its claims are scientifically validated consumer metrics and plans to defend the case in court. The lawsuit adds uncertainty as the company goes public, potentially affecting long-term brand credibility and customer retention if the company loses.
IPO Follows Strong 2025 Funding Round
Oura's October 2025 Series E round valued the company at about $11 billion and raised over $900 million MedTech Dive. Now, just nine months later, the company's IPO values it at $15.6 billion—a 42% bump in valuation. The company's IPO arrives amid a broader resurgence in U.S. technology listings Yahoo Finance.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
38
Articles
65
Reach
103
A
AnonymousAuthor
